IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
This study has been completed.
Sponsor:
University of Campania "Luigi Vanvitelli"
Collaborator:
Napoli CTO Hospital
Information provided by:
University of Campania "Luigi Vanvitelli"
ClinicalTrials.gov Identifier:
NCT01025934
First received: December 3, 2009
Last updated: NA
Last verified: December 2009
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.
| Condition | Intervention | Phase |
|---|---|---|
| Proliferative Diabetic Retinopathy | Drug: Bevacizumab Other: sham | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Official Title: | Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy |
Resource links provided by NLM:
Further study details as provided by University of Campania "Luigi Vanvitelli":
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 7 days | Drug: Bevacizumab |
| Active Comparator: 20 days | Drug: Bevacizumab |
| Sham Comparator: sham | Other: sham |
Eligibility| Ages Eligible for Study: | Child, Adult, Senior |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- vitreous haemorrhage
- tractional retinal detachment
- active proliferative diabetic retinopathy.
Exclusion Criteria:
- neovascular glaucoma
- cataract
- combined traction and rhegmatogenous RD
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
No Contacts or Locations Provided
No Contacts or Locations Provided
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT01025934 History of Changes |
| Other Study ID Numbers: |
IVBDRNA |
| Study First Received: | December 3, 2009 |
| Last Updated: | December 3, 2009 |
Additional relevant MeSH terms:
|
Retinal Diseases Diabetic Retinopathy Eye Diseases Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Diabetes Complications Diabetes Mellitus |
Endocrine System Diseases Bevacizumab Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antineoplastic Agents |
ClinicalTrials.gov processed this record on September 21, 2017